Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q3 2025 · 10-Q
Revenue$26.07M$26.07M+22.3% vs Q3 2024 Net Income$779.00K$779.00KN/M vs Q3 2024 EPS Diluted$0.04$0.04N/M vs Q3 2024 Gross Profit$17,516,000+30.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived$3,202,000+78.8% Free Cash Flowderived$3,192,000+80.0% Margins · derivedGross margin67.2%+4.1 pt vs Q3 2024
Operating margin7.9%+48.0 pt vs Q3 2024
Net margin3.0%+45.8 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 7, 2025 · 38 d after period end